###### Strengths and limitations of this study

-   This is the first study evaluating the safety of increasing potassium intake with supplements on circulating potassium and renal function, based on randomised controlled trials.

-   As none of the trials had serum--plasma potassium and creatinine as primary outcomes, the studies may have been underpowered for an effect on these variables.

-   The results are only generalisable to the type of patients and individuals who took part in the trials considered (people with hypertension, with and without therapy, normotensives, high-risk groups, non-smokers and random sample of the general population).

-   The source of heterogeneity was identified. However, the removal of the heterogeneity did not alter substantially the pooled estimate.

-   The study shows that a short-term moderate increase in potassium intake using supplements (average 45 mmol or 1755 mg/day; range 22--140 mmol or 858--5460 mg/day) is safe and void of risk of hazardous hyperkalaemia or renal deterioration in healthy people and patients, even using blockers of the renin--angiotensin system, whose kidney function is not impaired.

Background {#s1}
==========

A high potassium (K) intake lowers blood pressure (BP) in people with hypertension and, to a lesser extent, in people with normal BP.[@R1] [@R2] However, the beneficial effects of K extend beyond BP, and it may include a reduction in the risk of stroke (independent of BP changes).[@R1] [@R3] [@R4]

The K intake in the Western world is relatively low,[@R4] and a lower K intake has been associated with increased risks of cardiovascular disease, especially stroke.[@R1] [@R3] In randomised controlled trials (RCTs), a moderate increase in K intake, either as supplement or with diet, reduces BP,[@R1] [@R2] and the WHO has recently issued global recommendations for a target dietary K intake of ≥90 mmol/day (≥3510 mg/day) for adults.[@R5] [@R6]

Different approaches may be adopted to achieve a minimum daily K intake.[@R7] They are dietary modification, use of salt substitutes and K supplementation. Dietary modifications would involve substituting potassium-low foods with fruits, vegetables, beans and nuts.[@R8] They would be appropriate for population-based primary prevention strategies, although it is generally costly and not always equitable. Salt substitutes are commercially available salt mixtures, in which the proportion of sodium chloride is substituted with K and magnesium salts.[@R9] Their use reduces BP and sodium consumption, concurrently increasing K intake.[@R10] This strategy is being considered in China to reduce hypertension.[@R11] [@R12] Supplementation with a K salt represents a cheap intervention to achieve a minimum daily target.[@R1] It is acceptable to many patients and has been advocated as a potential cost-effective adjunct in the secondary prevention of stroke.[@R7]

However, there have been concerns that a widespread moderate increase in K, especially when given as supplementation, could be harmful, leading to hazardous hyperkalaemia.[@R2] [@R13] Furthermore, the proposal of replacing sodium chloride with K-based salt in food manufacturing has also been opposed as potentially harmful.[@R16] [@R17]

Given the potential usefulness and cost-effectiveness of K supplementation, we decided to update the most comprehensive systematic review carried out to date on the effects of K supplements on a variety of cardiovascular and biochemical outcomes.[@R1] However, at the time neither circulating K nor creatinine levels were included in the outcomes of interest. We therefore carried out an updated systematic review and a meta-analysis of RCTs of K supplementation using the same search strategy to estimate the effects that moderate supplementation of K has on serum levels and renal function.

Data and methods {#s2}
================

Study selection {#s2a}
---------------

We updated a systematic review carried out as part of a WHO review of the effects of K on cardiovascular risk factors, published in 2013.[@R1] We replicated the search strategy outlined in the paper extending it to papers published from 25 August 2011 to 10 July 2015. The search strategy is shown in [online supplementary](#SM1){ref-type="supplementary-material"} S1. We kept the same criteria as originally defined. In brief, we planned to include only RCTs (individual and cluster randomised). RCTs must have allocated at least one group of participants to increased K intake (intervention) and one group to lower K intake (control) for at least 4 weeks. RCTs had to use urinary K excretion from 24-hour urine collections to estimate actual K intake. The RCTs could not have concomitant interventions (ie, non-drug interventions, antihypertensive drugs or other drugs) in the intervention group unless those interventions were also applied to the control group, so the only difference between the groups was the level of K intake. We excluded studies targeting acutely ill or HIV-positive people, people admitted to hospital or people with impaired urinary K excretion due to a medical condition or drug treatment. The searches were run on MEDLINE and Embase with no language restriction. After downloading the abstracts and deleting duplicates, abstracts were scanned. We also included 25 articles selected from the original WHO search.[@R1] Studies that met the following inclusion criteria were then selected for the present analysis: (1) RCTs, (2) the intervention group should be K supplement and (3) serum or plasma K levels should be reported. A total of 20 studies were included (13 from the papers published from 2011 to 2015 and 7 from the previous review; [figure 1](#BMJOPEN2016011716F1){ref-type="fig"} and see [online supplementary](#SM1){ref-type="supplementary-material"} S2 and S3). The systematic review and the meta-analysis followed the PRISMA guidelines (see [online supplementary](#SM1){ref-type="supplementary-material"} Checklist).

![PRISMA flow diagram.](bmjopen2016011716f01){#BMJOPEN2016011716F1}

10.1136/bmjopen-2016-011716.supp1

Data extraction, risk of bias and quality assessment {#s2b}
----------------------------------------------------

Data extraction was performed in duplicate to counteract human errors and individual biases (LAB and FPC). In addition to extracting relevant data on K supplementation, serum or plasma K and creatinine levels, urinary sodium and K excretions, information was gathered from individual studies to compose a study characteristics table ([table 1](#BMJOPEN2016011716TB1){ref-type="table"}) which incorporated descriptive and methodological details about the design of the trials, treatment tested and outcomes measured. When data or copies were not available, authors were contacted to provide information. Data extraction sheets were checked by the review team, and differences were resolved by discussion. For the meta-analysis, means and SDs of outcome measures were extracted for the K supplementation and control groups at the end of each intervention period (for crossover studies), and for baseline and post-treatment period (for parallel-group studies). We assessed the risk of bias quantitatively using the rating scale developed by Downs and Black[@R18] ([table 1](#BMJOPEN2016011716TB1){ref-type="table"} and see [online supplementary](#SM1){ref-type="supplementary-material"} S4) and qualitatively using the Cochrane Collaboration\'s tool[@R19] (see [online supplementary](#SM1){ref-type="supplementary-material"} S5 and S6). For RCTs, we assessed the risk of bias associated with the method of sequence generation (possible selection bias), allocation concealment (possible selection bias), blinding (possible performance bias), selective reporting (possible selective reporting bias), loss to follow-up (possible attrition bias) and completeness of reporting outcome data (possible attrition bias). We rated the risk of bias as being low, unclear or high according to established PRISMA criteria. We used funnel plots to assess the presence of small study bias. We generated 'risk of bias graph' and 'risk of bias summary' figures (see [online supplementary](#SM1){ref-type="supplementary-material"} S5 and S6).

###### 

Characteristics of the studies included in the meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)      Country           Population              Participants (n)     Age (range), years   Design                Quality\*   Control                         Potassium                Duration (weeks)   Quantity of K (mmol/day)   Urinary K (mmol/day)   Plasma/serum K (mmol/L)   Comment
  ------------------ ----------------- ----------------------- -------------------- -------------------- --------------------- ----------- ------------------------------- ------------------------ ------------------ -------------------------- ---------------------- ------------------------- --------------------------------------------------------------------
  MacGregor (1982)   UK                HPT                     23\                  45 (26--66)          RCT-DBX               25          Placebo                         KCl (slow-K)             4                  64                         Pl: 62\                Pl: 3.84\                 
                                                               12 men; 18 white                                                                                                                                                                   K: 118                 K: 4.02                   

  Richards (1984)    New Zealand       HPT                     12                   (19--52)             RCT-X (not blinded)   23          Control diet                    KCl (elixir)             4                  140                        C: ∼60\                C: 3.84\                  Control diet 180 Na/ 60 K
                                                                                                                                                                                                                                                  K: ∼170                K: 3.99                   

  Bulpitt (1985)     UK                HPT                     33 (K=14; C=19)\     55                   RCT-P (open)          21          No supplement                   KCl (slow-K)             12                 64                         C: 55\                 C: 3.5\                   On loop diuretics
                                                               55% women                                                                                                                                                                          K: 95                  K: 3.8                    

  Kaplan (1985)      USA               HPT with hypokalaemia   16\                  48.8 (35--66)        RCT-DBX               25          Placebo                         KCl                      6                  60                         Pl: 36\                Pl: 3.00\                 Hypokalaemic on diuretics
                                                               10 women; 13 black                                                                                                                                                                 K: 82                  K: 3.56                   

  Smith (1985)       UK                HPT                     20\                  53 (30--66)          RCT-DBX               26          Placebo                         KCl (slow-K)             4                  64                         Pl: 67\                Pl: 3.9\                  Reduced Na to 70
                                                               11 men; 18 white                                                                                                                                                                   K: 117                 K: 4.1                    

  Zoccali (1985)     UK                HPT                     19\                  M: 41 (26--53)\      RCT-SBX               20          Placebo (lactose)               KCl (Selora)             2                  100                        Pl: 58\                Pl: 3.9\                  Selora (92% KCl, 6% K gluconate, 1% Ca silicate, 1% glutamic acid)
                                                               10 men               W: 35 (26--53)                                                                                                                                                K: 139                 K: 4.0                    

  Matlou (1986)      South Africa      HPT                     32\                  51 (34--62)          RCT-SBX               21          Placebo (teaspoon as glucose)   KCl (teaspoon as salt)   6                  65                         Pl: 52\                Pl: 3.87\                 
                                                               Black women                                                                                                                                                                        K: 114                 K: 4.32                   

  Grobbee (1987)     The Netherlands   HPT                     40\                  (18--28)             RCT-DBX               23          Placebo                         KCl (slow-K)             6                  72                         Pl: 74\                Pl: 3.76\                 Na restriction
                                                               34 men                                                                                                                                                                             K: 131                 K: 4.00                   

  Siani (1987)       Italy             HPT                     37\                  45 (21--61)          RCT-DBP               25          Placebo                         KCl (Lento-Kalium)       15                 48                         Pl: 57\                Pl: 4.4\                  
                                                               23 men                                                                                                                                                                             K: 87                  K: 4.3                    

  Barden (1987)      Australia         NT                      44\                  (18--55)             RCT-DBX               20          Placebo                         KCl (slow-K)             4                  80                         Pl: ∼55\               Pl: 3.725\                Dietary K \<60 mmol/day
                                                               women                                                                                                                                                                              K: ∼115                K: 3.86                   

  Obel (1989)        Kenya             HPT                     48\                  40                   RCT-DBP               21          Placebo                         KCl (slow-K)             16                 64                         Pl: 62\                Pl: 4.0\                  
                                                               black                                                                                                                                                                              K: 102                 K: 4.0                    

  Patki (1990)       India             HPT                     37\                  49.9                 RCT-DBX               24          Placebo                         KCl (Kesol B, liquid)    8                  60                         Pl: 60\                Pl: 3.6\                  
                                                               8 men                                                                                                                                                                              K: 82                  K: 3.7                    

  Valdes (1991)      Chile             HPT                     24                                        RCT-DBX               23          Placebo                         KCl                      4                  64                         Pl: 55\                Pl: 3.8\                  
                                                                                                                                                                                                                                                  K: 123                 K: 4.1                    

  Fotherby (1992)    UK                HPT                     18\                  75 (66--79)          RCT-DBX               26          Placebo                         KCl                      4                  60                         Pl: 60\                Pl: 4.3\                  
                                                               5 men                                                                                                                                                                              K: 99                  K: 4.4                    

  Geleijnse (1994)   The Netherlands   General population      100                  (55--75)             RCT-DBP               24          Control (common salt)           KCl (mineral salt)       24                 22                         Pl: 86\                Pl: 4.23\                 Mineral salt: 41% KCl, 17% Mg salt, 1% trace minerals
                                                                                                                                                                                                                                                  K: 97                  K: 4.35                   

  Kawano (1998)      Japan             HPT                     55\                  62.3 (36--77)        RCT-DBX               20          Placebo                         KCl (slow-K)             4                  64                         Pl: 54\                Pl: 4.15\                 
                                                               26 men                                                                                                                                                                             K: 96                  K: 4.42                   

  He (2010)          UK                HPT                     42\                  51 (18--75)          RCT-DBX               26          Placebo                         KCl (slow-K)\            4\                 64\                        Pl: 77\                Pl: 4.4\                  
                                                               30 men                                                                                                      KHCO~3~                  4                  64                         KCl: 122\              KCl: 4.6\                 
                                                                                                                                                                                                                                                  KHCO~3~: 125           KHCO~3~: 4.4              

  Yusuf (2012)       India             High risk               518\                 57.5                 RT-Open label         16          None                            KCl                      8                  30                         --\                    Pre: 4.3\                 
                                                               308 men                                                                                                                                                                            --                     K: 4.4                    

  Graham (2014)      North Ireland     HPT CVD\>10%            40\                  54.8 (40--70)        RCT-DBX               23          Placebo                         KCl (slow-K)             6                  64                         --\                    Pl: 3.9\                  On doxazosin;\
                                                               32 men                                                                                                                                                                             --                     K: 4.1                    6 weeks washout

  Gijsbers (2015)    The Netherlands   Non-smokers             36\                  65.8\                RCT-DBX               25          Placebo                         KCl capsules             4                  72                         Pl: 55.3\              Pl: 4.29\                 Untreated
                                                               24 men\              (47--80)                                                                                                                                                      K: 118.1               K: 4.41                   
                                                               white                                                                                                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Downs and Black score (max 27).

C, control; DB, double blind; HPT, hypertension; K, potassium; P, parallel group; Pl, placebo; RCT, randomised controlled trial; SB, single blind; X, crossover.

Data synthesis and analysis {#s2c}
---------------------------

Comparisons were made between the K supplementation and control groups with reference to the change between post-treatment groups in crossover trials and differences in changes from baseline to post-treatment groups in parallel-group trials. Changes were calculated such that a positive difference represents an increase and a negative difference a reduction in the outcome measure in the K-supplemented group compared to placebo or control. Weighted mean differences (WMDs) between the effect of treatment and control were estimated using a random-effect model.[@R20] The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. The method is based on the inverse-variance approach, making an adjustment to the study weights according to the extent of variation, or heterogeneity, among the varying intervention effects. For each outcome, data from all trials were entered into a funnel plot. Asymmetry of the plot was visually examined and formally tested by Egger\'s test[@R21] to detect publication bias. Statistical heterogeneity among studies was assessed by χ^2^ test and the I^2^ statistic.[@R22] Comparisons with significant heterogeneity were followed up by sensitivity analysis in which one study was omitted at a time to identify the source of heterogeneity. If dropping the first study did not reduce heterogeneity to a non-significant level, a second study was removed, and so on. Subgroup analyses were also carried out to examine sources of heterogeneity attributable to the study characteristics. Exploratory groups were defined a priori to compare the effect of K supplementation according to sex, age groups, ethnicity, dose of K and duration of supplementation. All statistical analyses were performed using RevMan v.5.3.5. and STATA V.14.1.

Results {#s3}
=======

Twenty-one samples from the 20 studies were included^s1--s20^ ([figure 1](#BMJOPEN2016011716F1){ref-type="fig"} and see [online supplementary](#SM1){ref-type="supplementary-material"} S2). Excluded studies are listed in [online supplementary](#SM1){ref-type="supplementary-material"} S3.

Characteristics of the trials {#s3a}
-----------------------------

Eighteen studies recruited men and women, whereas two studies recruited only women.^s7\ s10^ Two studies only studied black participants^s7\ s11^ ([table 1](#BMJOPEN2016011716TB1){ref-type="table"}). They included 1216 participants from 12 different countries (6 from UK, 3 from The Netherlands, 2 each from New Zealand and India, 1 from USA, South Africa, Italy, Australia, Kenya, Chile, Japan and Northern Ireland). All but 2^s3\ s18^ were controlled with either placebo (n=16) or a control intervention (n=2; [table 1](#BMJOPEN2016011716TB1){ref-type="table"}). Fifteen used a crossover design, four had a parallel group and one was sequential. All studies used K chloride as supplement, and one had an additional arm with K bicarbonate.^s17^ The duration of supplementation varied from 2 to 24 weeks and the amount of K given from 22 to 140 mmol/day.

The effect of potassium supplementation on plasma and serum potassium {#s3b}
---------------------------------------------------------------------

In the pooled analysis, K supplementation caused a small increase in plasma or serum K levels (WMD 0.14 mmol/L, 95% CI 0.09 to 0.19, p\<1×10^−5^) with no evidence of publication bias (Egger\'s test p=0.65), no asymmetry detected by the 'trim and fill' method (see [online supplementary](#SM1){ref-type="supplementary-material"} S7) and some heterogeneity between studies (I^2^=57%, p=6×10^−4^; [figure 2](#BMJOPEN2016011716F2){ref-type="fig"}). The effects on plasma or serum K showed a significant variation by dose given (test of subgroup differences: p=0.02) (see [online supplementary](#SM1){ref-type="supplementary-material"} S8). However, it did not appear that there was a dose-dependent effect (meta-regression p=0.62; see [online supplementary](#SM1){ref-type="supplementary-material"} S9), although most of the doses were in a narrow range of 50--75 mmol/day (see [online supplementary](#SM1){ref-type="supplementary-material"} S10 and S11). The effect increased from 0.11 mmol/L (0.06, 016) in those without concomitant drug therapy to 0.17 (0.01, 0.34) and 0.42 (0.17, 0.68) in those with concomitant drug therapy whether including or excluding ACE-inhibitors (ACE-i) or angiotensin receptor blockers (ARB) (test of subgroup differences: p=0.05; see [online supplementary](#SM1){ref-type="supplementary-material"} S12). The greatest increase was seen in two studies of hypokalaemic patients in whom the objective was to restore their plasma levels.^s3\ s6^ The effects were not associated with the geographic area of the world where trials were performed (test of subgroup differences: p=0.13; see [online supplementary](#SM1){ref-type="supplementary-material"} S13) or the average age of the participants (meta-regression p=0.82; see [online supplementary](#SM1){ref-type="supplementary-material"} S14). To rule out the influence of poor-quality trials on the overall estimate, we repeated the analysis only in double-blind randomised placebo-controlled crossover trials (n=12). The estimate of effect was 0.19 mmol/L (95% CI 0.12 to 0.25, p\<1×10^−5^; I^2^=42%, p=0.05). We also estimated the pooled effect in trials of hypertensive patients only (n=16; WMD 0.19 mmol/L, 95% CI 0.13 to 0.26, p\<1×10^−5^; I^2^=49%, p=0.01).

![Forest plot of the effect of potassium supplementation on serum or plasma potassium levels in randomised clinical trials.](bmjopen2016011716f02){#BMJOPEN2016011716F2}

The effect of potassium supplementation on urinary potassium excretion {#s3c}
----------------------------------------------------------------------

K supplementation caused a significant increase in urinary K excretion (WMD 45.75 mmol (1784 mg) per day, 95% CI 37.81 to 53.69, p\<1×10^−5^; [figure 3](#BMJOPEN2016011716F3){ref-type="fig"}). The dose of K had a significant effect on the change in urinary K (meta-regression p=0.001; [figure 4](#BMJOPEN2016011716F4){ref-type="fig"}). While confirming that the urinary excretion of K is a good biomarker of K intake, most studies used between 48 and 100 mmol of K per day, with only 2 studies of those providing urinary potassium below and above these levels.^s2\ s15^ When these studies were removed in a sensitivity analysis, the effect remained virtually unchanged (WMD 46.04 mmol (1795 mg) per day, 95% CI 39.33 to 52.75, p\<1×10^−5^).

![Forest plot of the effect of potassium supplementation on urinary potassium excretion in randomised clinical trials.](bmjopen2016011716f03){#BMJOPEN2016011716F3}

![Meta-regression analysis of the changes in urinary potassium excretion for the dose of potassium given.](bmjopen2016011716f04){#BMJOPEN2016011716F4}

The effect of potassium supplementation on plasma and serum creatinine {#s3d}
----------------------------------------------------------------------

K supplementation did not cause any change in renal function as measured by serum or plasma creatinine levels (WMD 0.30 µmol/L, 95% CI −1.19 to 1.78, p=0.70; [figure 5](#BMJOPEN2016011716F5){ref-type="fig"}). There was some publication bias (Egger\'s test p=0.047); however, the 'trim and fill' method did not show asymmetry in the funnel plot (see [online supplementary](#SM1){ref-type="supplementary-material"} 15). No heterogeneity was detected (I^2^=9%, p=0.35).

![Forest plot of the effect of potassium supplementation on serum or plasma creatinine levels in randomised clinical trials.](bmjopen2016011716f05){#BMJOPEN2016011716F5}

The effect of potassium supplementation on urinary sodium excretion {#s3e}
-------------------------------------------------------------------

K supplementation did not cause a significant change in urinary sodium excretion (WMD 4.42 mmol (75.2 mg) per day, 95% CI −4.84 to 13.69, p=0.35) (see [online supplementary](#SM1){ref-type="supplementary-material"} S16). However, there was heterogeneity between studies (I^2^=55%, p=0.003), fully accounted for by one study (using a salt substitute)^s15^. When removed, a small natriuretic effect of K was detected (WMD 7.42 mmol (126.1 mg) per day, 95% CI 1.26 to 13.58, p=0.02; see [online supplementary](#SM1){ref-type="supplementary-material"} S17) (I^2^=0%, p=0.86).

Tolerability {#s3f}
------------

No serious hazardous side effects were reported in any trial ([table 2](#BMJOPEN2016011716TB2){ref-type="table"}).

###### 

Tolerability of potassium supplementation and reported adverse reactions in the published papers

  Study              Description
  ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MacGregor (1982)   All patients who entered the trial completed it without any adverse effect.
  Richards (1984)    The study was completed without incident.
  Bulpitt (1985)     The patients were asked about any symptom of indigestion. Three reported of the symptom before being given K supplementation but not afterwards, and one patient in the control group lost this symptom. One patient in each group started to complain of a decrease in appetite at the end of the trial.
  Kaplan (1985)      None of the 16 patients had notable changes in clinical status or symptoms during the 16-week trial.
  Smith (1985)       Nothing reported. No withdrawals.
  Zoccali (1985)     Four patients were withdrawn, one because the first treatment (Selora salt) precipitated diarrhoea, two because they were unable to tolerate the taste of the K preparation and one because the diastolic BP after the placebo phase had risen to 120 mm Hg. Twelve patients interviewed after the study commented on the unpleasant taste of the K preparation.
  Matlou (1986)      Three patients dropped out, one was admitted to hospital with an intercurrent illness and was given moduretic, and two failed consistently to keep their appointments.
  Grobbee (1987)     Nothing reported. All participants entering the double-blind study completed it.
  Siani (1987)       All patients completed the trial without suffering any adverse effects.
  Barden (1987)      Forty-three women completed the trial, with one withdrawing during the first treatment period.
  Obel (1989)        All 48 patients completed the trial. None developed any notable untoward effect attributable to medication.
  Patki (1990)       Three patients given placebo, four given K, and four given K and Mg reported of pain in the abdomen and nausea, but this passed off and did not require withdrawal of treatment.
  Valdes (1991)      Nothing reported.
  Fotherby (1992)    There were no withdrawals from the study. All patients took at least 90% of the trial medication (...) which was well tolerated with no reported adverse effects.
  Geleijnse (1994)   Complete follow-up was achieved by 97 of the 100 randomised participants. Two of the controls withdrew after 8 and 16 weeks because of admission to hospital for symptoms not related to intervention. One person withdrew in the mineral salt group after 6 weeks because of dislike of the foods. (...) Reports of side effects and lifestyle changes during intervention were minimal and equally distributed among the study groups.
  Kawano (1998)      One patient withdrew due to gastrointestinal symptoms during K supplementation.
  He (2010)          Four patients withdrew from the study (reasons not given).
  Yusuf (2012)       Twenty-seven (10.5%) of those receiving K+ supplements permanently discontinued this (11 for dyspepsia, 4 for elevated creatinine or K+, 12 for other reasons).
  Graham (2014)      The main side effect was that of gastrointestinal irritation. This was reported by four participants, while taking potassium chloride. Symptoms resolved with a reduction in potassium supplementation from 64 mmol/4.8 g (8 tablets) to 48 mmol/3.6 g daily (6 tablets). No participant withdrew from the study as a result of this side effect.
  Gijsbers (2015)    Reported side effects in participants\' diaries indicated that 19 persons experienced gastrointestinal symptoms during sodium, 21 during potassium and 8 during placebo supplementation (P=0.004). Other side effects including dizziness, headache, illness, shortness of breath and oedema were not significantly different among the three treatments.

Discussion {#s4}
==========

In the present meta-analysis of RCTs, increasing K intake by moderate K supplementation (average 45 mmol (1755 mg) per day) causes a small increase in serum K levels (0.17 mmol/L) and no change in renal function. The effect on serum K does not vary with the dose given (from 22 to 140 mmol (from 858 to 5460 mg) per day), with the duration of the supplementation (2--24 weeks), the presence or absence of concomitant drug therapy, including the presence of blockers of the renin--angiotensin system, and with age or geographic location.

To the best of our knowledge, this is the first study evaluating the safety of increasing K intake with supplements on serum K and renal function, based on RCTs.

Strengths and limitations {#s4a}
-------------------------

Our analysis followed the CONSORT guidelines and assessed the risk of bias qualitatively and quantitatively. As none of the trials had been designed to assess the effect of K supplements on serum K and creatinine as primary outcomes, the studies may have been underpowered for an effect of these variables. However, given the narrow variability of these measurements and the standard laboratory methods used to determine them, the meta-analytical approach will have compensated by giving more statistical power for the pooled estimates. The source of heterogeneity was identified in three trials. However, their removal, while removing the heterogeneity, did not alter substantially the pooled estimate. These results add to previous evidence of safety of these supplements on other biomarkers like total cholesterol, triglyceride and catecholamine levels.[@R1]

RCTs and systematic reviews are reliable methods of determining the effects of treatment.[@R23] Their usefulness in providing evidence that would influence practice would depend on their internal validity (their quality in design and conduct to minimise erroneous conclusions) and their external validity (their applicability and generalisability in clinical settings).[@R23] [@R24] Lack of external validity has always been the most frequent criticism by clinicians of RCTs, systematic reviews and guidelines.[@R23] It has been argued that the results of trials should be assumed to be externally valid unless there are specific reasons to put this assumption into significant doubt.[@R23] Most trials included in the meta-analysis (16 out of 20) were carried out in people with hypertension, while in 2 studies on diuretics and with hypokalaemia.^s3\ s6^ The remainder were carried out in normotensives,^s10^ a high-risk group,^s18^ non-smokers^s20^ and in a random sample of the general population.^s15^ The results are therefore generalisable to this type of participants only. The reviewed trials had not included people or patients with renal impairment. Sensitivity analyses did not suggest differences according to patients\' characteristics like gender, age and type of underlying condition. However, these subgroup analyses have limited margin of interpretation. For instance, only 3 studies were conducted in patients with a mean age of \>60 years.^s14\ s16\ s20^ In individual trials, irrespective of dose of K, duration of supplementation or the presence and type of concomitant pharmacological therapy, changes in serum K were below 0.3 mmol/L, with the exception of 2 studies.^s6−s7^ In one study,^s6^ patients were selected on the basis that they had clinically significant diuretic-induced hypokalaemia; the supplementation increased serum K by 0.56 mmol/L, restoring it within the normal range. In another study,^s7^ only black women were recruited who had lower K intake (urinary excretion 52 mmol (2028 mg) per day) and a tendency to lower serum K (3.87 mmol/L). The supplementation increased serum K by 0.45 mmol/L with levels within the normal range.

What is the evidence of hazard? {#s4b}
-------------------------------

Some international bodies discourage the use of K supplements or K-rich salt replacers as likely cause of hazardous hyperkalaemia.[@R2] [@R12] Generally, these warnings, while applied to the general population, are based on case reports referring to either sick patients with end-stage kidney disease ignoring medical advice on K intake restrictions or excessive intakes leading to increases in serum K levels of several millimoles per litre with severe hyperkalaemia.[@R25] In 5 cases,[@R30] [@R31] individuals suffered serious hyperkalaemia and in 2 cases fatal hyperkalaemia (serum K 8.9 and 10.8 mmol/L) following K overdoses of up to 723 mmol (28 200 mg) in a day. In other reports,[@R25] [@R26] [@R28] [@R29] individuals with severe renal impairment and, in some cases, already of haemodialysis[@R28] abused K-containing salt substitutes. Finally, 2 Afro-Caribbean men on antihypertensive therapy including ACE-inhibitors[@R27] presented with serum K levels of 7.6 and 7.0 mmol/L following daily use of 70 mmol (2730 mg) and 133 mmol (5187 mg) of K added to their food daily as a salt substitute. We agree that caution should be exercised in people with severe impairments of their renal function when considering potassium supplements. However, our analysis suggests that a more 'moderate' supplement does not seem to cause severe hyperkalaemia or deterioration in renal function in people with normal renal function, even in the presence of drugs that block the renin--angiotensin--aldosterone system.

Benefits of potassium supplements {#s4c}
---------------------------------

The consideration of the use of moderate increases in K intake with supplements is encouraged by the evidence of potential benefits in controlling hypertension,[@R1] [@R4] a surrogate end point for cardiovascular risk, stroke in particular. While the evidence of a potential benefit of K on stroke prevention in humans is mainly derived from observational cohort studies,[@R1] [@R3] early animal experiments indicated that the reduction in mortality of stroke-prone hypertensive rats given K supplements was seen even in BP-matched animals,[@R32] [@R33] suggesting that, in rats, K reduces stroke rates also through mechanisms other than BP reduction. Subsequent evidence showed a protective vascular effects of K, especially in thrombus formation.[@R7] High K increases the lumen of cerebral arteries,[@R34] inhibition of atherosclerotic vascular lesions, decreases vascular smooth muscle cell proliferation and migration, decreases free radical formation, reduces LDL-cholesterol oxidation and decreases platelet aggregation.[@R35] [@R36] These results have supported recent calls for considering trials of a moderate increase in K intake with supplements to test whether this is a viable and potentially cost-effective strategy to prevent stroke incidence in high-risk groups and stroke recurrence.[@R7]

How can we increase potassium intake? {#s4d}
-------------------------------------

Increasing K intake through diet is an efficacious method to lower BP.[@R37] It would involve increasing the consumption of K-rich foods like fruits, vegetables, beans and nuts.[@R8] While the dietary approach is the basis of public health programmes promoting healthy eating, it is generally costly and difficult to implement in low socioeconomic groups[@R38] [@R39] as well as among vulnerable patients at high risk, like elderly people who may find it difficult to change their diet, and would widen health inequalities. The addition of K through salt substitutes or supplements is an alternative cheap intervention to achieve daily targets. The quantity of K can be titrated more precisely, and it is acceptable to many people. Caution should be exercised in people who suffer from kidney disease and have renal dysfunction, or in those who may be on antialdosterone therapy.

Conclusions {#s5}
===========

The present study shows that a moderate increase in K intake using supplements could be safe and void of risk of hazardous hyperkalaemia or renal deterioration in people and patients whose kidney function is not impaired, even using blockers of the renin--angiotensin system. Given the limitations of the analysis to younger patient groups and short-term supplementations, and the potential benefit as an adjunct preventive strategy,[@R7] these results should encourage feasibility trials to ascertain the generalisability of these findings to patients with normal renal function at high risk of stroke.
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